

**Clinical trial results:**

**A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine in Taiwan when co-administered with GSK Biologicals' Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine as a 3-dose primary immunization course at 1.5; 3 and 6 months of age and GSK Biologicals' Rotarix vaccine (HRV) as a 2-dose primary immunization course at 1.5 and 3 months of age.**

**Summary**

EudraCT number	2015-001511-12
Trial protocol	Outside EU/EEA
Global end of trial date	06 June 2008

**Results information**

Result version number	v2 (current)
This version publication date	09 April 2021
First version publication date	29 July 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li><li>Minor correction in safety section.</li></ul>

**Trial information****Trial identification**

Sponsor protocol code	109861
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00533507
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 October 2008
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 June 2008
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine in Taiwan, one month post dose 3, when co-administered with GSK Biologicals' Infanrix hexa and GSK Biologicals' Rotarix vaccines

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 September 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Taiwan: 230
Worldwide total number of subjects	230
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	230
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Synflorix group
-----------	-----------------

Arm description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Arm type	Experimental
Investigational medicinal product name	Synflorix
Investigational medicinal product code	
Other name	10Pn-PD-DiT, Pneumococcal conjugate vaccine GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The vaccine was injected intramuscularly in the right thigh at 1.5, 3 and 6 months of age.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	DTPa-HBV-IPV/Hib
Pharmaceutical forms	Powder and suspension for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The vaccine was injected intramuscularly in the left thigh, at 1.5, 3 and 6 months of age.

Investigational medicinal product name	Rotarix
Investigational medicinal product code	
Other name	HRV vaccine
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

The vaccine was administered orally at 1.5 and 3 months of age.

<b>Number of subjects in period 1</b>	Synflorix group
Started	230
Completed	229
Not completed	1
Consent withdrawn by subject	1

## Baseline characteristics

### Reporting groups

Reporting group title	Synflorix group
-----------------------	-----------------

Reporting group description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Reporting group values	Synflorix group	Total	
Number of subjects	230	230	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: weeks			
arithmetic mean	6.4		
standard deviation	± 0.6	-	
Gender categorical			
Units: Subjects			
Female	115	115	
Male	115	115	

## End points

### End points reporting groups

Reporting group title	Synflorix group
Reporting group description: Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.	

### Primary: Concentration of Anti-Protein D Antibodies

End point title	Concentration of Anti-Protein D Antibodies <sup>[1]</sup>
End point description: Concentrations are given as geometric mean concentrations (GMC) and expressed in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).	
End point type	Primary
End point timeframe: One month after the third dose	
Notes:	

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.  
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Concentration of Anti-Protein D Antibodies	2277.6 (2048.7 to 2532.1)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Concentration of Anti-Pneumococcal Antibodies

End point title	Concentration of Anti-Pneumococcal Antibodies <sup>[2]</sup>
End point description: Concentrations are given as geometric mean titers (GMC) and expressed in microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.	
End point type	Primary
End point timeframe: One month after the third dose	
Notes:	

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.  
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was

performed.

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1	2.92 (2.65 to 3.22)			
Anti-4	3.79 (3.42 to 4.19)			
Anti-5	4.5 (4.11 to 4.93)			
Anti-6B	1.69 (1.47 to 1.94)			
Anti-7F	4.07 (3.72 to 4.46)			
Anti-9V	3.9 (3.51 to 4.32)			
Anti-14	5.69 (5.1 to 6.35)			
Anti-18C	7.28 (6.43 to 8.25)			
Anti-19F	8.04 (7.37 to 8.78)			
Anti-23F	2.81 (2.44 to 3.22)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-Protein D Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Protein D Antibody Concentrations Above the Cut-Off Value
End point description: Anti-protein D antibody cut-off value assessed was greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).	
End point type	Secondary
End point timeframe: Before the first dose (pre) and one month after (post) the third dose	



End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Pre (N=217)	38			
Post (N=219)	218			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value
-----------------	---

End point description:

Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

End point type	Secondary
----------------	-----------

End point timeframe:

Before the first dose (pre) and one month after (post) the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Anti-1 Pre (N=217)	111			
Anti-1 Post (N=219)	219			
Anti-4 Pre (N=217)	85			
Anti-4 Post (N=219)	219			
Anti-5 Pre (N=217)	149			
Anti-5 Post (N=219)	219			
Anti-6B Pre (N=217)	107			
Anti-6B Post (N=219)	215			
Anti-7F Pre (N=218)	138			
Anti-7F Post (N=219)	219			
Anti-9V Pre (N=218)	123			
Anti-9V Post (N=219)	219			
Anti-14 Pre (N=218)	203			
Anti-14 Post (N=219)	219			
Anti-18C Pre (N=219)	153			
Anti-18C Post (N=219)	219			
Anti-19F Pre (N=219)	172			
Anti-19F Post (N=219)	219			
Anti-23F Pre (N=219)	91			
Anti-23F Post (N=219)	216			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value
End point description: Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value	
End point type	Secondary
End point timeframe: One month after the third dose	

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Anti-6A (N=219)	210			
Anti-19A (N=218)	200			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-Off Value

End point title	Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-Off Value
End point description: Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.	
End point type	Secondary
End point timeframe: One month after the third dose	

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	103			
Units: Subjects				
Opsono-1 (N=102)	98			
Opsono-4 (N=103)	103			
Opsono-5 (N=102)	101			
Opsono-6B (N=102)	89			
Opsono-7F (N=103)	103			
Opsono-9V (N=98)	98			
Opsono-14 (N=102)	101			
Opsono-18C (N=101)	99			
Opsono-19F (N=103)	101			
Opsono-23F (N=102)	98			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Opsonophagocytic Activity Against Cross-Reactive Pneumococcal Serotypes Above the Cut-Off Value

End point title	Number of Subjects With Opsonophagocytic Activity Against Cross-Reactive Pneumococcal Serotypes Above the Cut-Off Value
End point description:	Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.
End point type	Secondary
End point timeframe:	One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: Subjects				
Opsono-6A	87			
Opsono-19A	38			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value
End point description: Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was greater than or equal to 0.15 microgram per milliliter (µg/mL).	
End point type	Secondary
End point timeframe: One month after the third dose	

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-Polyribosyl-Ribitol Phosphate	58			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-Diphtheria and Anti-Tetanus Toxoids Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Diphtheria and Anti-Tetanus Toxoids Antibody Concentrations Above the Cut-Off Value
End point description: Anti-diphtheria and anti-tetanus toxoids antibody cut-off values assessed were greater than or equal to 0.10 International Units per milliliter (IU/mL).	
End point type	Secondary
End point timeframe: One month after the third dose	

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-diphtheria toxoid	58			
Anti-tetanus toxoid	58			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-Pertussis (PT), Anti-Filamentous

## Hemagglutinin (FHA) and Anti-Pertactin (PRN) Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Pertussis (PT), Anti-Filamentous Hemagglutinin (FHA) and Anti-Pertactin (PRN) Antibody Concentrations Above the Cut-Off Value
-----------------	--

End point description:

Anti-PT, anti-FHA and anti-PRN cut-off values assessed were greater than or equal to 5 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the third dose

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-PT (N=58)	58			
Anti-FHA (N=58)	58			
Anti-PRN (N=57)	57			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value
-----------------	--

End point description:

Anti-HBs antibody cut-off value assessed was greater than or equal to 10 milli-International Units per milliliter (mIU/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the third dose

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Subjects				
Anti-Hepatitis B Surface Antigen (HBs)	32			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-Poliovirus 1, 2 and 3 Antibody Titers Above the Cut-Off Value

End point title	Number of Subjects With Anti-Poliovirus 1, 2 and 3 Antibody Titers Above the Cut-Off Value
-----------------	--

End point description:

Anti-poliovirus 1, 2 and 3 antibody cut-off value assessed was greater than or equal to 1:8 titer.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the third dose

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Subjects				
Anti-poliovirus 1	44			
Anti-poliovirus 2	44			
Anti-poliovirus 3	44			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Anti-rotavirus Immunoglobulin A antibody concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-rotavirus Immunoglobulin A antibody concentrations Above the Cut-Off Value
-----------------	---

End point description:

Anti-rotavirus IgA antibody cut-off value assessed was greater than or equal to 20 Units per milliliter (U/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

Four months after the administration of the second dose of Rotarix™ vaccine

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Subjects				
Anti-rotavirus Immunoglobulin A	44			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting solicited local symptoms

End point title	Number of subjects reporting solicited local symptoms
-----------------	---

End point description:

Solicited local symptoms assessed include pain, redness and swelling.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 4-day (Day 0-3) period after any dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
Pain	146			
Redness	144			
Swelling	139			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting unsolicited adverse events (AE)

End point title	Number of subjects reporting unsolicited adverse events (AE)
-----------------	--

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

End point type	Secondary
----------------	-----------

End point timeframe:

During the 31-day (Day 0-30) period after each dose

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
AEs	95			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting serious adverse events (SAE)

End point title	Number of subjects reporting serious adverse events (SAE)
End point description: An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.	
End point type	Secondary
End point timeframe: Up to one month after the third dose	

<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
SAEs	15			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with solicited general symptoms

End point title	Number of subjects with solicited general symptoms
End point description: Solicited general symptoms assessed include diarrhoea, drowsiness, fever, irritability, loss of appetite, and vomiting	
End point type	Secondary
End point timeframe: During the 4-day (Day 0-3) period after any dose	



<b>End point values</b>	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
Diarrhoea	7			
Drowsiness	190			
Fever	153			
Irritability	203			
Loss of appetite	159			
Vomiting	55			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: during the 4 days (Day 0-Day 3) following vaccination.

Unsolicited AEs: during the 31 days (Day 0-Day 30) following vaccination.

SAEs: during the entire study.

Adverse event reporting additional description:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	11.0
--------------------	------

### Reporting groups

Reporting group title	Synflorix Group
-----------------------	-----------------

Reporting group description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Serious adverse events	Synflorix Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 230 (6.52%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	2 / 230 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Enterocolitis			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial hyperreactivity			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis diaper			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Vesicoureteric reflux			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	6 / 230 (2.61%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	4 / 230 (1.74%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	2 / 230 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis bacterial			

subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Kawasaki's disease			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meningitis aseptic			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Synflorix Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	224 / 230 (97.39%)		
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	146 / 230 (63.48%)		
occurrences (all)	146		
Redness			
alternative assessment type: Systematic			

subjects affected / exposed	144 / 230 (62.61%)		
occurrences (all)	144		
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed	139 / 230 (60.43%)		
occurrences (all)	139		
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed	190 / 230 (82.61%)		
occurrences (all)	190		
Fever			
alternative assessment type: Systematic			
subjects affected / exposed	153 / 230 (66.52%)		
occurrences (all)	153		
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	203 / 230 (88.26%)		
occurrences (all)	203		
Loss of appetite			
alternative assessment type: Systematic			
subjects affected / exposed	159 / 230 (69.13%)		
occurrences (all)	159		
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	55 / 230 (23.91%)		
occurrences (all)	55		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	54 / 230 (23.48%)		
occurrences (all)	54		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 November 2007	This amendment is made following the request from the country to perform immunogenicity analyses of the co-administered vaccines in a subset of subjects.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported